TCAI's EPLive 2026 Spotlights a New Frontier in Cardiac Arrhythmia Care

AUSTIN, Texas – June 25, 2026

A record-breaking gathering of the world's leading cardiac electrophysiology experts took place in Austin this past May, as the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its eighth international symposium, EPLive 2026. The two-day event drew an unprecedented 1,600 participants from across the globe, including Belgium, Brazil, Canada, Colombia, and Italy, all converging—virtually and in-person—to witness and discuss the latest advancements in treating complex cardiac arrhythmias. The symposium underscores a growing global demand for collaborative, hands-on education in a field undergoing rapid transformation.

A New Era of Collaboration and Education

At the heart of EPLive 2026's success is its unique and highly effective educational model: live case demonstrations broadcast directly from the state-of-the-art Electrophysiology Center at St. David's Medical Center. This immersive format provided physicians, advanced practice registered nurses, and allied health professionals with a front-row seat to complex procedures, complete with real-time expert commentary. This approach moves beyond theoretical lectures, offering practical insights that attendees can integrate into their own clinical practice to improve patient outcomes.

"The record number of participants at EPLive 2026 is a reflection of the growing demand for practical, case-based education and collaboration," said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., the trailblazing cardiac electrophysiologist who serves as executive medical director of TCAI and as the EPLive course director. "By sharing knowledge, innovation and experience in that setting, we help accelerate advancements in cardiovascular care and improve outcomes for the millions of people worldwide living with heart arrhythmias."

The event's global prestige was further amplified by contributions from some of the world's most respected medical institutions. The four sessions featured a mix of live and recorded cases not only from TCAI but also from premier centers including the Cleveland Clinic, Massachusetts General, and the University of Pennsylvania in the United States, as well as the Centro Cardiologico Monzino in Italy and the International Arrhythmia Center at Cardioinfantil Foundation in Colombia. This international collaboration fostered a rich exchange of techniques and perspectives, solidifying EPLive's role as a vital nexus for the global electrophysiology community. For their participation, physicians could earn up to 14.5 AMA PRA Category 1 Credit™ hours, highlighting the significant educational value of the symposium.

Pioneering Procedures Take Center Stage

EPLive 2026 served as a showcase for revolutionary technologies and techniques pioneered by TCAI physicians, offering a glimpse into the future of arrhythmia treatment. Two procedures, in particular, captured the attention of attendees for their potential to make treatments safer, more efficient, and more effective.

One of the highlights was a streamlined approach that combines two critical treatments—atrial fibrillation (A Fib) ablation and left atrial appendage occlusion (LAAO)—into a single procedure. For patients with A Fib who face a higher risk of stroke, this combined therapy addresses both rhythm control and stroke prevention simultaneously. Historically, these might have required separate interventions, each with its own set of risks and recovery periods. By integrating them, physicians can reduce the need for multiple procedures, shorten procedure times, and minimize the potential for complications, representing a significant leap forward in patient-centered care.

The symposium also prominently featured the latest innovations in pulsed field ablation (PFA), a disruptive technology that is rapidly becoming the new standard of care. Unlike traditional ablation methods that use extreme heat or cold to destroy problematic cardiac tissue, PFA employs short-duration, high-energy electrical pulses. This non-thermal energy is remarkably tissue-selective, precisely targeting the heart muscle cells responsible for arrhythmias while sparing surrounding delicate structures like the esophagus and phrenic nerve. The result is a significantly enhanced safety profile. TCAI has been at the vanguard of this shift, having performed the first commercially approved PFA procedure in the United States earlier in 2024, following the technology's FDA approval. The rapid adoption of PFA, with U.S. market penetration soaring in recent months, underscores the industry's recognition of its game-changing benefits.

TCAI: A Leader in a Rapidly Evolving Field

The success and influence of EPLive 2026 are a direct reflection of the stature of its host, the Texas Cardiac Arrhythmia Institute. Recognized as a leading robotic electrophysiology center in North America, TCAI has cultivated a reputation as an international hub for treatment, training, and research dedicated exclusively to heart rhythm disorders. Its six advanced electrophysiology labs are equipped with the most sophisticated technology available, enabling its team of world-renowned physicians to perform a high volume of the most complex procedures.

Leading this team is Dr. Andrea Natale, a figure synonymous with innovation in electrophysiology. Dr. Natale is credited with pioneering catheter-based ablation for atrial fibrillation and has been instrumental in developing many of the techniques that are now standard practice worldwide. His work has been published in hundreds of peer-reviewed articles, and he serves as editor-in-chief for the Journal of Atrial Fibrillation. His leadership has cemented TCAI's position at the forefront of a medical field experiencing explosive growth.

The global electrophysiology market is projected to swell from approximately $12.5 billion in 2025 to over $21 billion by 2030, driven by an aging population, the rising prevalence of cardiac arrhythmias, and a torrent of technological innovation. In this fiercely competitive landscape, TCAI continues to distinguish itself not just by hosting educational events, but by actively shaping the future of the discipline through research and early adoption of groundbreaking technologies.

Cementing Austin's Status as a Medical Innovation Hub

Beyond its impact on cardiovascular medicine, EPLive 2026 shines a bright light on Austin, Texas, reinforcing its growing reputation as a major center for healthcare innovation. Drawing 1,600 of the world's top medical minds to the city for a landmark event elevates its international profile, attracting talent and investment that ripple throughout the local economy and medical community.

The symposium is just one example of the pioneering work happening at TCAI and St. David's Medical Center. This pattern of leadership is consistent. In July 2025, the institute was the first in the nation to implant a novel FDA-approved leadless system for cardiac resynchronization therapy. More recently, in May 2026, its physicians were the first in the U.S. to implant the world's smallest catheter-delivered defibrillation lead. Each of these milestones demonstrates a relentless commitment to providing patients with access to the most advanced care possible.

By fostering an environment of innovation, education, and global collaboration, the Texas Cardiac Arrhythmia Institute is not only advancing the standard of care for patients with heart rhythm disorders worldwide but is also solidifying Austin's place on the map as a critical hub for medical progress.